News

Scinai Immunotherapeutics Establishes US CDMO Business Unit

December 19, 2024

Scinai Bioservices Inc. has been established in Delaware as the company's new US-based subsidiary, which will serve biotech companies in early stage drug development.

AbbVie to Boost Immunology Pipeline with Acquisition of Nimble Therapeutics

December 18, 2024

AbbVie's latest acquisition target is Nimble Therapeutics, which will give AbbVie a lead asset, an oral peptide for treating psoriasis.

Electronic Product Information Moves Forward in Europe

December 17, 2024

A pilot program to explore creation and testing of ePIs in regulatory procedures shows positive results.

Novo Nordisk to Establish New Production Facility for Rare Disease Therapies in Denmark with DKK 8.5 Billion Investment

December 17, 2024

Novo Nordisk will use the DKK 8.5 billion (US$1.2 billion) to build a new modular and flexible production facility in Odense, Denmark, that will produce multiple products for rare diseases.

Several Orphan Drugs Among Medicines Recommended for Approval by EMA in December

December 16, 2024

EMA recommended 17 drugs for marketing authorization in December, including treatments for rare heart conditions, anemia, and liver disease.

FDA Creates CDER Center for Real-World Evidence Innovation

December 13, 2024

The Center for Drug Evaluation and Research’s new center will coordinate and promote use of real-word data in regulatory decisions.

TekniPlex Healthcare to Announce Expanded Capacity at Pharmapack Europe

December 13, 2024

The company will be showcasing its injection blow molded bottles and five-layer blown film at the packaging event in Paris on Jan. 22–23, 2025.

Intertek Teams Up with CrystecPharma on Formulation and Development of Dry Powder Inhaler Products

December 13, 2024

The partners will aim to establish a platform that enables rapid development of DPI products.

GSK Enters into Strategic Collaborations with Relation and Muna to Advance Drug Development

December 12, 2024

With these agreements, the respective parties will work to advance therapeutic candidates for treating fibrotic diseases, osteoarthritis, and Alzheimer’s disease.

BioMarin to Increase Production Capacity with €60 Million Expansion at Ireland Facility

December 12, 2024

With this investment, BioMarin will add a new laboratory to its Shanbally, Co. Cork, Ireland, manufacturing facility.